vs
HARVARD BIOSCIENCE INC（HBIO）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
HARVARD BIOSCIENCE INC的季度营收约是RIVERVIEW BANCORP INC的1.7倍（$23.7M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -12.0%，领先21.8%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -3.3%），HARVARD BIOSCIENCE INC自由现金流更多（$-545.0K vs $-736.0K），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -1.6%）
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
HBIO vs RVSB — 直观对比
营收规模更大
HBIO
是对方的1.7倍
$14.0M
营收增速更快
RVSB
高出13.7%
-3.3%
净利率更高
RVSB
高出21.8%
-12.0%
自由现金流更多
HBIO
多$191.0K
$-736.0K
两年增速更快
RVSB
近两年复合增速
-1.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $23.7M | $14.0M |
| 净利润 | $-2.8M | $1.4M |
| 毛利率 | 59.7% | — |
| 营业利润率 | 7.2% | 12.4% |
| 净利率 | -12.0% | 9.8% |
| 营收同比 | -3.3% | 10.4% |
| 净利润同比 | -15916.7% | 11.8% |
| 每股收益（稀释后） | $-0.06 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HBIORVSB
| Q4 25 | $23.7M | $14.0M | ||
| Q3 25 | $20.6M | $13.6M | ||
| Q2 25 | $20.4M | $13.3M | ||
| Q1 25 | $21.8M | $12.9M | ||
| Q4 24 | $24.6M | $12.7M | ||
| Q3 24 | $22.0M | $12.8M | ||
| Q2 24 | $23.1M | $12.2M | ||
| Q1 24 | $24.5M | $9.0M |
净利润HBIORVSB
| Q4 25 | $-2.8M | $1.4M | ||
| Q3 25 | $-1.2M | $1.1M | ||
| Q2 25 | $-2.3M | $1.2M | ||
| Q1 25 | $-50.3M | $1.1M | ||
| Q4 24 | $18.0K | $1.2M | ||
| Q3 24 | $-4.8M | $1.6M | ||
| Q2 24 | $-2.9M | $966.0K | ||
| Q1 24 | $-4.7M | $-3.0M |
毛利率HBIORVSB
| Q4 25 | 59.7% | — | ||
| Q3 25 | 58.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.0% | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 58.1% | — | ||
| Q2 24 | 57.2% | — | ||
| Q1 24 | 60.3% | — |
营业利润率HBIORVSB
| Q4 25 | 7.2% | 12.4% | ||
| Q3 25 | 1.0% | 10.2% | ||
| Q2 25 | -4.0% | 11.7% | ||
| Q1 25 | -228.1% | 11.3% | ||
| Q4 24 | 0.0% | 12.4% | ||
| Q3 24 | -8.5% | 15.5% | ||
| Q2 24 | -9.0% | 10.0% | ||
| Q1 24 | -9.3% | -47.5% |
净利率HBIORVSB
| Q4 25 | -12.0% | 9.8% | ||
| Q3 25 | -6.0% | 8.1% | ||
| Q2 25 | -11.2% | 9.2% | ||
| Q1 25 | -231.2% | 8.9% | ||
| Q4 24 | 0.1% | 9.7% | ||
| Q3 24 | -21.9% | 12.2% | ||
| Q2 24 | -12.7% | 7.9% | ||
| Q1 24 | -19.1% | -34.7% |
每股收益（稀释后）HBIORVSB
| Q4 25 | $-0.06 | $0.07 | ||
| Q3 25 | $-0.03 | $0.05 | ||
| Q2 25 | $-0.05 | $0.06 | ||
| Q1 25 | $-1.14 | $0.05 | ||
| Q4 24 | $0.01 | $0.06 | ||
| Q3 24 | $-0.11 | $0.07 | ||
| Q2 24 | $-0.07 | $0.05 | ||
| Q1 24 | $-0.11 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.6M | $28.6M |
| 总债务越低越好 | $35.9M | — |
| 股东权益账面价值 | $13.7M | $164.2M |
| 总资产 | $80.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 2.61× | — |
8季度趋势，按日历期对齐
现金及短期投资HBIORVSB
| Q4 25 | $8.6M | $28.6M | ||
| Q3 25 | $6.8M | $32.8M | ||
| Q2 25 | $7.4M | $34.2M | ||
| Q1 25 | $5.5M | $29.4M | ||
| Q4 24 | $4.1M | $25.3M | ||
| Q3 24 | $4.6M | $31.0M | ||
| Q2 24 | $4.0M | $27.8M | ||
| Q1 24 | $4.3M | $23.6M |
总债务HBIORVSB
| Q4 25 | $35.9M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $34.9M | — | ||
| Q1 25 | $36.4M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $34.9M | — | ||
| Q2 24 | $35.7M | — | ||
| Q1 24 | $35.6M | — |
股东权益HBIORVSB
| Q4 25 | $13.7M | $164.2M | ||
| Q3 25 | $14.1M | $163.5M | ||
| Q2 25 | $15.7M | $162.0M | ||
| Q1 25 | $14.8M | $160.0M | ||
| Q4 24 | $63.3M | $158.3M | ||
| Q3 24 | $65.3M | $160.8M | ||
| Q2 24 | $67.2M | $155.9M | ||
| Q1 24 | $68.8M | $155.6M |
总资产HBIORVSB
| Q4 25 | $80.1M | $1.5B | ||
| Q3 25 | $78.0M | $1.5B | ||
| Q2 25 | $80.1M | $1.5B | ||
| Q1 25 | $79.8M | $1.5B | ||
| Q4 24 | $126.6M | $1.5B | ||
| Q3 24 | $131.2M | $1.5B | ||
| Q2 24 | $128.9M | $1.5B | ||
| Q1 24 | $133.2M | $1.5B |
负债/权益比HBIORVSB
| Q4 25 | 2.61× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.22× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-96.0K | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-545.0K | $-736.0K |
| 自由现金流率自由现金流/营收 | -2.3% | -5.2% |
| 资本支出强度资本支出/营收 | 1.9% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $5.5M | $20.4M |
8季度趋势，按日历期对齐
经营现金流HBIORVSB
| Q4 25 | $-96.0K | $-506.0K | ||
| Q3 25 | $1.1M | $16.8M | ||
| Q2 25 | $2.8M | $-697.0K | ||
| Q1 25 | $3.0M | $8.3M | ||
| Q4 24 | $1.7M | $2.2M | ||
| Q3 24 | $-842.0K | $764.0K | ||
| Q2 24 | $-846.0K | $5.4M | ||
| Q1 24 | $1.4M | $12.8M |
自由现金流HBIORVSB
| Q4 25 | $-545.0K | $-736.0K | ||
| Q3 25 | $877.0K | $16.4M | ||
| Q2 25 | $2.7M | $-773.0K | ||
| Q1 25 | $2.5M | $5.6M | ||
| Q4 24 | $1.4M | $1.9M | ||
| Q3 24 | $-1.7M | $-1.4M | ||
| Q2 24 | $-1.7M | $5.3M | ||
| Q1 24 | $758.0K | $7.1M |
自由现金流率HBIORVSB
| Q4 25 | -2.3% | -5.2% | ||
| Q3 25 | 4.3% | 120.1% | ||
| Q2 25 | 13.0% | -5.8% | ||
| Q1 25 | 11.4% | 43.1% | ||
| Q4 24 | 5.8% | 15.0% | ||
| Q3 24 | -7.8% | -11.3% | ||
| Q2 24 | -7.2% | 43.7% | ||
| Q1 24 | 3.1% | 79.0% |
资本支出强度HBIORVSB
| Q4 25 | 1.9% | 1.6% | ||
| Q3 25 | 1.0% | 2.9% | ||
| Q2 25 | 0.4% | 0.6% | ||
| Q1 25 | 2.4% | 21.0% | ||
| Q4 24 | 1.2% | 2.4% | ||
| Q3 24 | 4.0% | 17.3% | ||
| Q2 24 | 3.5% | 0.9% | ||
| Q1 24 | 2.6% | 62.0% |
现金转化率HBIORVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | 95.83× | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
RVSB
暂无分部数据
